Abstract
Background
In 123I-metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy, the early heart-to-mediastinum (H/M) ratio is considered to reflect the density of the cardiac sympathetic nerve endings, washout rate (WR) is an indicator of the cardiac sympathetic tone, and the delayed H/M ratio reflects both. The Delayed H/M ratio is usually used to support the diagnosis of Lewy body diseases (LBDs) and idiopathic REM sleep behavior disorder (iRBD); however, which values should be used have not been specified. Here, we hypothesized that the combination of these values is appropriate for the diagnostic purpose.
Methods
In this single-center retrospective cohort study, we recruited 106 patients with LBDs or iRBD and 33 patients without those diseases, of whom we reviewed the 123I-MIBG myocardial scintigraphy results.
Results
Sensitivity/specificity to diagnose LBDs and iRBD were 0.77/0.94 for the early H/M ratio (≤ 2.0), 0.82/0.94 for the delayed H/M ratio (≤ 2.0), and 0.89/0.91 for WR (≥ 23.0). When patients were considered positive if at least either the early H/M ratio or WR was abnormal, the sensitivity significantly increased to 0.97, whereas the specificity remained similar at 0.91. Furthermore, our subgroup analyses revealed that WR enhancement preceded H/M ratio reduction, but, in patients with a severely reduced early H/M ratio, paradoxically normal WR could be observed.
Conclusion
We propose the highly sensitive, combined early H/M ratio and WR assessments for 123I-MIBG myocardial scintigraphy. The temporal precedence of cardiac sympathetic dysfunction over denervation and the floor effect in 123I-MIBG uptake may underlie the sensitivity improvement.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Differentiation of each Parkinsonian syndrome poses a huge challenge for clinicians. In fact, postmortem pathological studies revealed that the clinical diagnosis made even by experienced neurologists is often inaccurate [1,2,3,4,5,6]. Therefore, tools to aid the differential diagnosis are of prominent importance. Among them, 123I-metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy has been consistently reported as a powerful tool to distinguish Lewy body diseases [LBDs; i.e. pure autonomic failure (PAF), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB)] and idiopathic REM sleep behavior disorder (iRBD) from other mimicking diseases since its first application to neurological diseases in the 1990s [7,8,9,10,11,12,13,14,15,16]. Recently, reduced cardiac 123I-MIBG uptake was employed as one of supportive criteria in the clinical diagnostic criteria of PD [1] and as one of indicative biomarkers in that of DLB [17]. However, these criteria do not specify which quantification values obtained in 123I-MIBG myocardial scintigraphy, namely, the early heart-to-mediastinum (H/M) ratio, delayed H/M ratio, and wash-out rate (WR), should be used for diagnosis, although the delayed H/M ratio is empirically preferred [10, 12].
The early H/M ratio is considered to primarily reflect the density of the cardiac sympathetic nerve endings, WR is an indicator of the cardiac sympathetic tone, and the delayed H/M ratio reflects both [18,19,20,21,22]. A recent longitudinal imaging study using 18F-dopamine positron emission tomography suggested that dysfunction precedes denervation in the cardiac sympathetic nerves [23]; therefore, WR should theoretically be more sensitive than the delayed H/M ratio. However, the floor effect in radioisotope uptake can produce paradoxically normal WR in patients with severe cardiac sympathetic denervation and reduce the sensitivity of WR [24, 25]. Considering these two opposing facts, we hypothesized that the combined early H/M ratio and WR assessments of 123I-MIBG myocardial scintigraphy would be best suited for the diagnoses of LBDs and iRBD.
Methods
Patients
This was a single-center retrospective cohort study conducted at the Department of Neurology and Center for Sleep-related Disorders of Kansai Electric Power Hospital, a regional referral hospital in Osaka, Japan. The institutional review board approved the study protocol. Among 157 consecutive patients who underwent 123I-MIBG myocardial scintigraphy from May 2013 to February 2019, 11 patients with diabetes, peripheral neuropathy, and/or a history of heart failure were firstly excluded because 123I-MIBG uptake has been reported to decrease in these conditions. Seven more patients were also excluded because their definite final diagnosis could not be obtained. Finally, we included 106 patients with a final diagnosis of LBDs or iRBD and 33 patients with a final diagnosis of other diseases. Patients with LBDs included 63 PD, 8 DLB, and 3 PAF patients, all of whom were diagnosed according to the established clinical criteria at the last follow-up visit (follow-up duration 3.37 ± 1.96 years) [1, 17, 26], as well as 32 iRBD patients who underwent all-night polysomnography and were diagnosed as described in the International Classification of Sleep Disorders, third edition [27]. All-night polysomnography equipped with the standard montage for scoring sleep stages was conducted and scored according to the manual by the American Academy of Sleep Medicine [28]. Patients with other diseases included 3 multiple system atrophy (MSA), 4 progressive supranuclear palsy (PSP), 4 corticobasal syndrome (CBS), 5 Alzheimer disease (AD), 4 drug-induced parkinsonism, 5 idiopathic normal pressure hydrocephalus (iNPH), 2 essential tremor (ET), and 2 psychogenic movement disorder patients, all of whom were diagnosed clinically at the last follow-up visit (follow-up duration 3.87 ± 1.75 years) [29,30,31], as well as 4 obstructive sleep apnea syndrome (OSAS) patients who were diagnosed in accordance with the International Classification of Sleep Disorders, third edition [27]. Study flowchart is represented in Fig. 1. For background characteristics, the age, sex, and disease duration were gathered for all participants. Hoehn-Yahr stage, initial motor symptom (tremor or not), and the presence of dream enactment behavior (DEB) were investigated only for PD patients.
123I-MIBG myocardial scintigraphy
Medications that are well known to affect 123I-MIBG uptake, such as serotonin-noradrenaline reuptake inhibitors, tricyclic antidepressants, reserpine, and labetalol, were temporally stopped [32]. At rest in the supine position, 111 MBq of 123I-MIBG (Fujifilm Toyama Chemical, Co. Ltd, Tokyo, Japan) was intravenously injected. Using a dual-head γ camera (GE healthcare, Tokyo, Japan) with low-energy collimators, the anterior planar image of the chest was acquired 20 min (early phase) and 3 h (delayed phase) after injection. The photopeak of 123I was centered at 159 keV with a 20% energy window. Acquisition time was 3 min and a 256 × 256 matrix was used. For quantification of the result, regions of interests (ROIs) were drawn around the heart and the mediastinum. Average counts per pixel in the ROI of the heart (H) were divided by those in the ROI of the mediastinum (M) to calculate the H/M ratio. The H/M ratio in the early phase was designated as the early H/M ratio and that in the delayed phase was designated as the delayed H/M ratio. WR was calculated by the following formula: {[(early H) − (early M) − (delayed H) + (delayed M)] × 0.53/13}/[(early H) − (early M)] × 100 [33]. The institutional cut-off values were pre-determined from normal controls as “mean—[2 × standard deviation (SD)]” for the early and delayed H/M ratios, and as “mean + (2 × SD)” for WR in 1992 when the clinical use of 123I-MIBG myocardial scintigraphy was approved in Japan, and were 2.0, 2.0, and 23.0 for the early H/M ratio, delayed H/M ratio, and WR, respectively, which is similar to the value obtained in the previous study using similar collimators [33].
Statistical analysis
The statistical software R (version 3.4.0, freely available at https://www.R-project.org) was used for analyses. We used the Mann–Whitney U test for comparing the distribution of two-groups, the Kruskal–Wallis test followed by the the Steel–Dwass test for comparing the distribution of multiple-groups, and Spearman’s rank correlation coefficients (Rs) for correlation analyses. We also used Fisher’s exact test for the analyses of contingency tables and McNemar’s test for comparisons of the sensitivity and specificity. Receiver operating characteristic (ROC) analyses were performed to assess the diagnostic accuracy. To compare the area under the ROC curve (AUC) of ROC curves, we used the method described in DeLong et al. [34]. Data are expressed as mean ± SD. P value of less than 0.05 was considered statistically significant.
Results
The clinical characteristics are summarized in Table 1. The representative 123I-MIBG myocardial scintigraphy images of each disease were represented in Fig. 2.
The 123I-MIBG myocardial scintigraphy results are summarized in Table 2. Both early and delayed H/M ratios were significantly lower in LBDs (i.e. PD, PAF, and DLB) and iRBD than in other diseases [early, 1.70 ± 0.41 (LBDs and iRBD) vs. 2.32 ± 0.38 (other diseases), p < 0.01; delayed, 1.55 ± 0.40 (LBDs and iRBD) vs. 2.32 ± 0.35 (other diseases), p < 0.01] (Fig. 3a, b), and WR was significantly enhanced in LBDs and iRBD than in other diseases [31.08 ± 6.44 (LBDs and iRBD) vs. 20.00 ± 3.85 (other diseases), p < 0.01] (Fig. 3c). Among LBDs and iRBD, the early H/M ratio, the delayed H/M ratio and WR were not significantly different between each disease [early, 1.56 ± 0.30 (iRBD) vs. 1.77 ± 0.46 (PD) vs. 1.73 ± 0.06 (PAF) vs. 1.65 ± 0.27 (DLB), p = 0.21; delayed, 1.39 ± 0.24 (iRBD) vs. 1.65 ± 0.46 (PD) vs. 1.44 ± 0.15 (PAF) vs. 1.42 ± 0.22 (DLB), p = 0.09; WR, 32.42 ± 5.74 (iRBD) vs. 29.94 ± 6.60 (PD) vs. 33.55 ± 10.66 (PAF) vs. 33.73 ± 5.36 (DLB), p = 0.08] (Fig. 3d–f). However, when compared between iRBD and LBDs, the early H/M ratio and delayed H/M ratios were significantly lower in iRBD than in LBDs [early, 1.56 ± 0.30 (iRBD) vs. 1.76 ± 0.43 (LBDs), p = 0.04; delayed, 1.39 ± 0.24 (iRBD) vs. 1.62 ± 0.44 (LBDs), p = 0.02] but WR were not significantly different [32.42 ± 5.74 (iRBD) vs. 30.50 ± 6.68 (LBDs), p = 0.10]. Among diseases other than LBDs and iRBD, the early H/M ratio, delayed H/M ratio, and WR were similar between each disease [early, 2.60 ± 0.52 (MSA) vs. 2.48 ± 0.13 (PSP) vs. 2.48 ± 0.43 (CBS) vs. 2.14 ± 0.15 (AD) vs. 2.10 ± 0.59 (drug-induced) vs. 2.06 ± 0.27 (iNPH) vs. 2.25 ± 0.21 (ET) vs. 2.70 ± 0.57 (psychogenic) vs. 2.4 ± 0.29 (OSAS), p = 0.15; delayed, 2.71 ± 0.46 (MSA) vs. 2.43 ± 0.11 (PSP) vs. 2.47 ± 0.38 (CBS) vs. 2.18 ± 0.12 (AD) vs. 2.08 ± 0.58 (drug-induced) vs. 2.18 ± 0.39 (iNPH) vs. 2.24 ± 0.33 (ET) vs. 2.54 ± 0.39 (psychogenic) vs. 2.32 ± 0.16 (OSAS), p = 0.32; WR, 18.56 ± 3.50 (MSA) vs. 18.33 ± 1.11 (PSP) vs. 20.49 ± 4.84 (CBS) vs. 20.58 ± 0.97 (AD) vs. 23.01 ± 5.12 (drug-induced) vs. 19.98 ± 6.26 (iNPH) vs. 15.47 ± 1.20 (ET) vs. 21.59 ± 0.85 (psychogenic) vs. 20.03 ± 3.31 (OSAS), p = 0.31] (Supplementary Fig. 1). Both in PD and iRBD, the early and delayed H/M ratios had significant negative correlations with the disease duration (PD, early, Rs = − 0.33, p < 0.01; PD, delayed, Rs = − 0.28, p = 0.02; iRBD, early, Rs = − 0.37, p = 0.04; iRBD, delayed, Rs = − 0.46, p < 0.01) (Supplementary Fig. 2A and 2B). It was also observed that the early and delayed H/M ratios were significantly reduced in PD patients with DEB than in those without DEB [early, 1.44 ± 0.28 (PD with DEB) vs. 1.88 ± 0.47 (PD without DEB), p < 0.01; delayed, 1.33 ± 0.28 (PD with DEB) vs. 1.75 ± 0.47 (PD without DEB), p < 0.01] (Supplementary Fig. 3A and 3B) but WR were not significantly different [31.11 ± 6.19 (PD with DEB) vs. 29.45 ± 7.06 (PD without DEB), p = 0.29]. The Hoehn-Yahr stage and initial motor symptom (tremor or not) were not associated with the early or delayed H/M ratio in PD patients.
AUCs were 0.86 [95% confidence interval (CI) 0.79–0.92] for the early H/M ratio, 0.90 (95% CI 0.84–0.96) for the delayed H/M ratio, and 0.93 (95% CI 0.87–0.97) for WR (Fig. 4a). No statistically significant differences were found among these 3 AUCs [early vs. delayed, p = 0.34; early vs. WR, p = 0.11; delayed vs. WR, p = 0.35]. ROCs also demonstrated that pre-determined institutional cut-offs for the early H/M ratio (2.0), delayed H/M ratio (2.0), and WR (23.0) were reasonable (Fig. 4a). Using these cut-offs, sensitivity and specificity of the early H/M ratio for the diagnosis of LBD and iRBD were 0.77 and 0.94, respectively, of the delayed H/M ratio were 0.82 and 0.94, respectively, and of WR were 0.89 and 0.91, respectively (Fig. 4a, b). No statistically significant differences in sensitivity or specificity were found among the early H/M ratio, delayed H/M ratio, and WR [sensitivity and specificity, p = 0.54 and p = 1.00 (early vs. delayed); p = 0.07 and p = 1.00 (early vs. WR); p = 0.28 and p = 1.00 (delayed vs. WR)]. When patients were considered positive if at least either the early H/M ratio was ≤ 2.0 or WR was ≥ 23.0 (combined assessment), the sensitivity became significantly higher than individual assessments [0.97, p < 0.01 (vs. the early H/M ratio), p < 0.01 (vs. the delayed H/M ratio), p = 0.04 (vs. WR)] whereas the specificity remained similar [0.91, p = 1.00 (vs. the early H/M ratio), p = 1.00 (vs. the delayed H/M ratio), p = 1.00 (vs. WR)] (Fig. 4b).
To further assess the physiological background of the improvement in sensitivity with this combined assessment, we conducted serial subgroup analyses. First, the disease duration was compared between LBDs and iRBD patients with a normal early H/M ratio but an enhanced WR (subgroup 1–1), and those with a reduced early H/M ratio and an enhanced WR (subgroup 1–2) (Supplementary Fig. 4A). The disease duration was significantly shorter in subgroup 1–1 compared with subgroup 1–2 [2.71 ± 1.01 (subgroup 1–1) vs 5.58 ± 3.72 (subgroup 1–2) years, p < 0.01] (Supplementary Fig. 4B), suggesting that WR enhancement precedes early H/M ratio reduction. Restricting the analysis only to PD patients did not alter the result [2.63 ± 1.01 (PD in subgroup 1–1) vs 3.86 ± 1.01 (PD in subgroup 1–2) years, p < 0.01]. Next, the disease duration was compared between LBDs and iRBD patients with a normal delayed H/M ratio but an enhanced WR (subgroup 2–1), and those with a reduced delayed H/M ratio and an enhanced WR (subgroup 2–2) (Fig. 5a). The disease duration was significantly shorter in subgroup 2–1 than in subgroup 2–2 [2.87 ± 1.13 (subgroup 2–1) vs. 5.33 ± 3.68 (subgroup 2–2) years, p < 0.01] (Fig. 5b), suggesting that WR enhancement even precedes delayed H/M ratio reduction. Restricting the analysis only to PD patients did not alter the result [2.77 ± 1.17 (PD in subgroup 2–1) vs 3.65 ± 1.88 (PD in subgroup 2–2) years, p = 0.04]. Finally, the early H/M ratio was compared between LBDs and iRBD patients with a reduced early H/M ratio and an enhanced WR (subgroup 3–1), and those with a reduced early H/M ratio but a normal WR (subgroup 3–2) (Fig. 5c). The early H/M ratio was significantly reduced in subgroup 3–2 than in subgroup 3–1 [1.53 ± 0.23 (group 3–1) vs. 1.34 ± 0.14 (group 3–2), p < 0.01] (Fig. 5d), showing that WR can return to normal value in patients with severe cardiac sympathetic nerve denervation supposedly because of the floor effect in 123I-MIBG uptake.
Discussion
In this study, we have shown that the combined early H/M ratio and WR assessments yielded significantly higher sensitivity than individual assessments of the early H/M ratio, delayed H/M ratio, and WR without an associated reduction in specificity. Furthermore, our subgroup analyses revealed that temporal precedence of WR enhancement over H/M ratio reduction and the floor effect in 123I-MIBG uptake may underlie the sensitivity improvement in our combined assessment.
MIBG, an analog of guanethidine, behaves similarly to noradrenaline in terms of uptake and storage by the cardiac sympathetic nerve endings, and radiolabeling of MIBG with iodine-123 enables us to clinically evaluate the integrity of the cardiac sympathetic nervous system. Originally, in the 1980s, 123I-MIBG myocardial scintigraphy was shown to have a prognostic value in heart failure [35, 36]. Subsequently, in the 1990s, 123I-MIBG myocardial scintigraphy was applied to LBDs and shown to have a diagnostic value for LBDs [7, 8]. Evidences have accumulated from then on, and a meta-analysis revealed that pooled sensitivity and specificity were 82.6% and 89.2%, respectively, for the early H/M ratio, and 89.7% and 82.6%, respectively, for the delayed H/M ratio to differentiate PD from other neurodegenerative parkinsonian syndromes [11]. Another meta-analysis revealed that pooled sensitivity and specificity were 98% and 94%, respectively, for the delayed H/M ratio to differentiate DLB from other types of dementia [37]. Patients with iRBD, a large proportion of whom eventually developed LBDs [38], have also been shown to demonstrate reduced 123I-MIBG uptake [9, 39,40,41,42,43,44]; therefore, reduced 123I-MIBG uptake has been considered as a good biomarker to support the diagnoses of LBDs and iRBD. Previous studies revealed that independent assessments of the early H/M ratio, delayed H/M ratio, and WR produce a similar diagnostic accuracy [45]; however, considering the reported fact that reduced 123I-MIBG uptake usually begins in the delayed phase and progresses longitudinally [22], the delayed H/M ratio is empirically preferred for the diagnostic purpose. It have also been observed that WR enhancement could precede delayed H/M ratio reduction [19]; however, supposedly because of a paradoxical normal WR in severely denervated patients which was observed in our study, WR is usually avoided for diagnoses of LBDs and iRBD. Our combinational assessment is therefore a totally reasonable approach to overcome this disadvantage of WR and should be preferred in clinical practice to raise the diagnostic accuracy of 123I-MIBG myocardial scintigraphy.
Although beyond the scope of this study, our study also revealed that both early and delayed H/M ratios were significantly reduced in iRBD than in LBDs, and in PD patients with DEB than in those without DEB. Although an earliest study reported that the magnitude of 123I-MIBG uptake reduction was similar between iRBD and PD [9], subsequent reports showed that iRBD patients display significantly lower 123I-MIBG uptake than PD patients [40, 42]. Furthermore, previous studies with small participants also revealed that PD patients with clinical symptoms of RBD display significantly lower 123I-MIBG uptake than those without clinical symptoms of RBD [43, 46]. Therefore, our data and those previous data altogether suggest that the lesion responsible for RBD links closely to the cardiac sympathetic denervation and that the presence of RBD only mirrors a distinct pathological subtype in PD. This hypothesis is important especially because iRBD recently gathers a lot of attention as prodromal PD for developing a disease modification therapy [47]; therefore, future studies with larger cohorts are definitely warranted to examine this hypothesis.
There are several limitations to this study. First, although we took a long follow-up period, it would be unfeasible to totally eliminate a diagnostic bias due to the established usefulness of 123I-MIBG myocardial scintigraphy for the diagnosis of LBDs [1, 17]. Second, only the clinical diagnosis was employed as a reference standard. Finally, the number of patients without LBDs and iRBD was relatively small. Nevertheless, our study has a high clinical relevance in that we proposed a reasonable, easily-feasible approach of combined early H/M ratio and WR assessments, which showed significantly higher sensitivity without an associated reduction of specificity.
Availability of data and material
Raw data used in this analysis was deposited in OSF (Open Science Framework). View-only link to our data is https://osf.io/6fmhw/?view_only=fadff8b1a6544c398d7ce2e114f0e8a7.
References
Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://doi.org/10.1002/mds.26424
Tsukita K, Sakamaki-Tsukita H, Tanaka K et al (2019) Value of in vivo α-synuclein deposits in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 34:1452–1463. https://doi.org/10.1002/mds.27794
Tsukita K, Taguchi T, Sakamaki-Tsukita H et al (2018) The vagus nerve becomes smaller in patients with Parkinson’s disease: a preliminary cross-sectional study using ultrasonography. Parkinsonism Relat Disord 55:148–149. https://doi.org/10.1016/j.parkreldis.2018.06.002
Chelban V, Bocchetta M, Hassanein S et al (2019) An update on advances in magnetic resonance imaging of multiple system atrophy. J Neurol 266:1036–1045. https://doi.org/10.1007/s00415-018-9121-3
Romagnolo A, Fabbri M, Merola A et al (2018) Beyond 35 years of Parkinson’s disease: a comprehensive clinical and instrumental assessment. J Neurol 265:1989–1997. https://doi.org/10.1007/s00415-018-8955-z
Nicastro N, Wegrzyk J, Preti MG et al (2019) Classification of degenerative parkinsonism subtypes by support-vector-machine analysis and striatal 123I-FP-CIT indices. J Neurol 266:1771–1781. https://doi.org/10.1007/s00415-019-09330-z
Hakusui S, Yasuda T, Yanagi T et al (1994) A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 49:81–84. https://doi.org/10.1016/0165-1838(94)90023-x
Orimo S, Ozawa E, Nakade S et al (1999) (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 67:189–194. https://doi.org/10.1136/jnnp.67.2.189
Miyamoto T, Miyamoto M, Inoue Y et al (2006) Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology 67:2236–2238. https://doi.org/10.1212/01.wnl.0000249313.25627.2e
King AE, Mintz J, Royall DR (2011) Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord 26:1218–1224. https://doi.org/10.1002/mds.23659
Orimo S, Suzuki M, Inaba A, Mizusawa H (2012) 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative Parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 18:494–500. https://doi.org/10.1016/j.parkreldis.2012.01.009
Treglia G, Cason E, Stefanelli A et al (2012) MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res 22:43–55. https://doi.org/10.1007/s10286-011-0135-5
Yoshita M, Arai H, Arai H et al (2015) Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS ONE 10:e0120540. https://doi.org/10.1371/journal.pone.0120540
Giannoccaro MP, Donadio V, Incensi A et al (2015) Skin biopsy and I-123 MIBG scintigraphy findings in idiopathic Parkinson’s disease and parkinsonism: a comparative study. Mov Disord 30:986–989. https://doi.org/10.1002/mds.26189
Alves Do Rego C, Namer IJ, Marcel C et al (2018) Prospective study of relevance of 123I-MIBG myocardial scintigraphy and clonidine GH test to distinguish Parkinson’s disease and multiple system atrophy. J Neurol 265:2033–2039. https://doi.org/10.1007/s00415-018-8941-5
Yousaf T, Dervenoulas G, Valkimadi P-E, Politis M (2019) Neuroimaging in Lewy body dementia. J Neurol 266:1–26. https://doi.org/10.1007/s00415-018-8892-x
McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89:88–100. https://doi.org/10.1212/WNL.0000000000004058
Taki J, Yoshita M, Yamada M, Tonami N (2004) Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med 18:453–461. https://doi.org/10.1007/bf02984560
Kashihara K, Ohno M, Kawada S, Okumura Y (2006) Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson’s disease and dementia with Lewy bodies. J Nucl Med 47:1099–1101
van der Veen BJ, Al Younis I, de Roos A, Stokkel MPM (2012) Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions. J Nucl Cardiol 19:752–762. https://doi.org/10.1007/s12350-012-9539-4
Nakajima K, Nakata T (2015) Cardiac 123I-MIBG imaging for clinical decision making: 22-year experience in Japan. J Nucl Med 56(Suppl 4):11S–19S. https://doi.org/10.2967/jnumed.114.142794
Orimo S, Yogo M, Nakamura T et al (2016) (123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies. Ageing Res Rev 30:122–133. https://doi.org/10.1016/j.arr.2016.01.001
Lamotte G, Holmes C, Wu T, Goldstein DS (2019) Long-term trends in myocardial sympathetic innervation and function in synucleinopathies. Parkinsonism Relat Disord 67:27–33. https://doi.org/10.1016/j.parkreldis.2019.09.014
Bohnen NI, Kuwabara H, Constantine GM et al (2007) Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson’s disease. Neurosci Lett 424:185–189. https://doi.org/10.1016/j.neulet.2007.07.035
Martin WRW, Wieler M, Stoessl AJ, Schulzer M (2008) Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson’s disease. Ann Neurol 63:388–394. https://doi.org/10.1002/ana.21320
The consensus committee of the American Autonomic Society and the American Academy of Neurology (1996) Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 46:1470. https://doi.org/10.1212/wnl.46.5.1470
American Academy of Sleep Medicine (2014) International classification of sleep disorders. American Academy of Sleep Medicine, Darien
Iber C, Ancoli-Israel S, Andrew LC, Stuart FQ (2007) The AASM Manual for the scoring of sleep and associated events: rules Terminology and Technical Specifications. American Academy of Sleep Medicine, Westchester
Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676. https://doi.org/10.1212/01.wnl.0000324625.00404.15
Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853–864. https://doi.org/10.1002/mds.26987
Armstrong MJ, Litvan I, Lang AE et al (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80:496–503. https://doi.org/10.1212/WNL.0b013e31827f0fd1
Jacobson AF, Travin MI (2015) Impact of medications on mIBG uptake, with specific attention to the heart: comprehensive review of the literature. J Nucl Cardiol 22:980–993. https://doi.org/10.1007/s12350-015-0170-z
Matsuo S, Nakajima K (2015) Assessment of cardiac sympathetic nerve function using 123I-meta-iodobenzylguanidine scintigraphy: technical aspects and standardization. Ann Nucl Cardiol 1:27–34. https://doi.org/10.17996/ANC.01.01.27
DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845
Schofer J, Spielmann R, Schuchert A et al (1988) Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 12:1252–1258. https://doi.org/10.1016/0735-1097(88)92608-3
Henderson EB, Kahn JK, Corbett JR et al (1988) Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 78:1192–1199. https://doi.org/10.1161/01.cir.78.5.1192
Treglia G, Cason E (2012) Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging 22:111–117. https://doi.org/10.1111/j.1552-6569.2010.00532.x
Iranzo A, Fernández-Arcos A, Tolosa E et al (2014) Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS ONE 9:e89741. https://doi.org/10.1371/journal.pone.0089741
Koyama S, Tachibana N, Masaoka Y et al (2007) Decreased myocardial (123)I-MIBG uptake and impaired facial expression recognition in a patient with REM sleep behavior disorder. Mov Disord 22:746–747. https://doi.org/10.1002/mds.21450
Miyamoto T, Miyamoto M, Suzuki K et al (2008) 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 31:717–723. https://doi.org/10.1093/sleep/31.5.717
Oguri T, Tachibana N, Mitake S et al (2008) Decrease in myocardial 123I-MIBG radioactivity in REM sleep behavior disorder: two patients with different clinical progression. Sleep Med 9:583–585. https://doi.org/10.1016/j.sleep.2007.08.006
Kashihara K, Imamura T, Shinya T (2010) Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson’s disease. Parkinsonism Relat Disord 16:252–255. https://doi.org/10.1016/j.parkreldis.2009.12.010
Miyamoto T, Miyamoto M, Iwanami M, Hirata K (2011) Cardiac 123I-MIBG accumulation in Parkinson’s disease differs in association with REM sleep behavior disorder. Parkinsonism Relat Disord 17:219–220. https://doi.org/10.1016/j.parkreldis.2010.11.020
Miyamoto T, Miyamoto M, Iwanami M, Hirata K (2011) Follow-up study of cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Eur J Neurol 18:1275–1278. https://doi.org/10.1111/j.1468-1331.2011.03392.x
Tsujikawa K, Hasegawa Y, Yokoi S et al (2015) Chronological changes of 123I-MIBG myocardial scintigraphy and clinical features of Parkinson’s disease. J Neurol Neurosurg Psychiatry 86:945–951. https://doi.org/10.1136/jnnp-2015-310327
Nomura T, Inoue Y, Högl B et al (2010) Relationship between (123)I-MIBG scintigrams and REM sleep behavior disorder in Parkinson’s disease. Parkinsonism Relat Disord 16:683–685. https://doi.org/10.1016/j.parkreldis.2010.08.011
Heinzel S, Berg D, Gasser T et al (2019) Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord 34:1464–1470. https://doi.org/10.1002/mds.27802
Acknowledgements
We thank Dr. Takahiro Kamada for inspiring us to do this study. He died in January 2019, and we wish to dedicate this article to his memory. We also thank Drs. Hiroshi Chatani, Koji Tsuzaki, Naoko Uehara, Yuwa Oka, and Akihiro Kikuya for their support in conducting this study, and Editage (https://www.editage.com) for editing and reviewing this manuscript for English language.
Funding
This study was neither supported nor funded.
Author information
Authors and Affiliations
Contributions
KT, NT, and TH contributed to the study conception, study design, and data acquisition. KT primarily analyzed the data and did the statistical analyses. The first draft of the manuscript was written by KT. NT and TH revised the manuscript for important intellectual content. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest concerning this study. Outside this study, Naoko Tachibana received a research grant from Novartis Pharma K.K.
Ethics approval
This study was approved by the institutional review board of Kansai Electric Power Hospital and conducted according to the ethical standards issued by the Declaration of Helsinki.
Consent to participate and consent for publication
The details of this study was posted up in our hospital with our contact information. All patients were exempt by the institutional review board of Kansai Electric Power Hospital from providing written informed consent due to the retrospective design of this study; however, all patients had the chance to request the detailed explanation from us and opt out at any time.
Code availability
Not applicable.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Tsukita, K., Tachibana, N. & Hamano, T. Appropriate assessment method of 123I-MIBG myocardial scintigraphy for the diagnosis of Lewy body diseases and idiopathic REM sleep behavior disorder. J Neurol 267, 3248–3257 (2020). https://doi.org/10.1007/s00415-020-09992-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-020-09992-0